Characterization of cytokine release syndrome (CRS) and neurological events (NEs) in the phase I TRANSCEND NHL 001 trial of lisocabtagene maraleucel (liso-cel) for patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).

Jeremy S. Abramson,Tanya Siddiqi,Leo I. Gordon,Matthew A. Lunning,Michael Wang,Jon E. Arnason,A. Mehta,Enkhee Purev,David G. Maloney,Charalambos Andreadis,Alison R. Sehgal,Scott R. Solomon,Nilanjan Ghosh,Tina M. Albertson,Jacob Garcia,Ana Kostic,Daniel Li,Yeonhee Kim,Maria Lia Palomba

Characterization of cytokine release syndrome (CRS) and neurological events (NEs) in the phase I TRANSCEND NHL 001 trial of lisocabtagene maraleucel (liso-cel) for patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).

2020

Jeremy S. Abramson
Tanya Siddiqi
Leo I. Gordon
Matthew A. Lunning
Michael Wang
Jon E. Arnason
A. Mehta
Enkhee Purev
David G. Maloney
Charalambos Andreadis
Alison R. Sehgal
Scott R. Solomon
Nilanjan Ghosh
Tina M. Albertson
Jacob Garcia
Ana Kostic
Daniel Li
Yeonhee Kim
Maria Lia Palomba

e20046Background: Clinical studies of liso-cel show low incidences of severe CRS and NEs. Pts with high tumor burden and inflammation are at higher risk of CRS and NEs (Borrega, Hemasphere 2019). H...

Keywords:

Oncology
Pathology
B-cell lymphoma
Internal medicine
relapsed refractory
Cytokine release syndrome
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations